194 related articles for article (PubMed ID: 24916368)
41. Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.
Wachtell K; Devereux RB; Lyle PA
Curr Cardiol Rep; 2006 Sep; 8(5):356-64. PubMed ID: 16956451
[TBL] [Abstract][Full Text] [Related]
42. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
Tempelhof MW
South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
[No Abstract] [Full Text] [Related]
43. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
Dézsi CA
Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
[TBL] [Abstract][Full Text] [Related]
44. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Sealey JE; Parra D; Rosenstein R; Laragh JH
Hypertension; 2010 Mar; 55(3):e16; author reply e17. PubMed ID: 20083722
[No Abstract] [Full Text] [Related]
45. How should we play our hand when holding an ACE?
Beattie WS
Can J Anaesth; 2010 Aug; 57(8):720-4. PubMed ID: 20512539
[No Abstract] [Full Text] [Related]
46. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
47. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
Dabrowski R; Szwed H
Kardiol Pol; 2007 Apr; 65(4):440-5. PubMed ID: 17530565
[No Abstract] [Full Text] [Related]
48. Renin-Angiotensin-Aldosterone System and Migraine: A Systematic Review of Human Studies.
Sassi KLM; Martins LB; de Miranda AS; Teixeira AL
Protein Pept Lett; 2020; 27(6):512-519. PubMed ID: 31995000
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
50. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome.
Li XY; Sun JF; Hu SQ
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1375-1383. PubMed ID: 28387887
[TBL] [Abstract][Full Text] [Related]
51. The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.
Sica DA
Curr Hypertens Rep; 2010 Apr; 12(2):67-73. PubMed ID: 20424943
[TBL] [Abstract][Full Text] [Related]
52. Optimal renin-angiotensin system blockade-wishful thinking?
Makani H; Bangalore S; Messerli FH
Nat Rev Cardiol; 2013 Aug; 10(8):486. PubMed ID: 23817190
[No Abstract] [Full Text] [Related]
53. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.
Ferreira AJ; Santos RA; Bradford CN; Mecca AP; Sumners C; Katovich MJ; Raizada MK
Hypertension; 2010 Feb; 55(2):207-13. PubMed ID: 20038757
[TBL] [Abstract][Full Text] [Related]
54. [Angiotensin-2 type 1 receptors (AT1R) and cancers].
Dolley-Hitze T; Verhoest G; Jouan F; Le Pogamp P; Arlot-Bonnemains Y; Oger E; Belaud-Rotureau MA; Rioux-Leclercq N; Vigneau C
Nephrol Ther; 2013 Apr; 9(2):85-91. PubMed ID: 23332110
[TBL] [Abstract][Full Text] [Related]
55. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis.
Cheungpasitporn W; Thongprayoon C; Srivali N; O'Corragain OA; Edmonds PJ; Ungprasert P; Kittanamongkolchai W; Erickson SB
Nephrol Dial Transplant; 2015 Jun; 30(6):978-88. PubMed ID: 25800881
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in preventive cardiology: which drug to use and what to expect in light of the ONTARGET trial.
Cairns JA
Pol Arch Med Wewn; 2008 Jun; 118(6):335-8. PubMed ID: 18619187
[No Abstract] [Full Text] [Related]
57. Renin-angiotensin blockade is associated with increased mortality after vascular surgery.
Railton CJ; Wolpin J; Lam-McCulloch J; Belo SE
Can J Anaesth; 2010 Aug; 57(8):736-44. PubMed ID: 20524103
[TBL] [Abstract][Full Text] [Related]
58. Rationale for combining blockers of the renin-angiotensin system.
Azizi M; Wuerzner G
Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
[TBL] [Abstract][Full Text] [Related]
59. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
Giles TD
Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
[TBL] [Abstract][Full Text] [Related]
60. Reply: Optimal renin-angiotensin-aldosterone system blockade--wish fulfilled.
Nussberger J; Bohlender J
Nat Rev Cardiol; 2013 Aug; 10(8):486. PubMed ID: 23817186
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
